Phase III Randomized, Double-blind, Multicenter, Global Study of Monalizumab or Placebo in Combination with Cetuximab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Previously Treated With an Immune Checkpoint Inhibitor.

Brief Summary

Type:
Other

Study Type:
Treatment

Phase:
III

ClinicalTrials.gov Identifier:
NCT04590963

Study #:
STUDY00145987

Start Date:
Oct 07, 2021

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT04590963

View Complete Trial Details & Eligibility at ClinicalTrials.gov